Zacks: Analysts Anticipate Juno Therapeutics Inc (JUNO) to Post -$1.15 EPS

Equities analysts predict that Juno Therapeutics Inc (NASDAQ:JUNO) will report ($1.15) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Juno Therapeutics’ earnings. Juno Therapeutics posted earnings of ($0.65) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 76.9%. The firm is expected to report its next earnings report on Wednesday, March 7th.

According to Zacks, analysts expect that Juno Therapeutics will report full-year earnings of ($3.34) per share for the current year. For the next year, analysts forecast that the company will post earnings of ($4.26) per share, with EPS estimates ranging from ($4.35) to ($4.17). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that that provide coverage for Juno Therapeutics.

Juno Therapeutics (NASDAQ:JUNO) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The firm had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. During the same quarter last year, the business earned ($0.57) earnings per share. Juno Therapeutics’s revenue was up 115.4% compared to the same quarter last year.

JUNO has been the topic of a number of analyst reports. Maxim Group restated a “buy” rating and set a $56.00 target price (up previously from $34.00) on shares of Juno Therapeutics in a research report on Monday, October 9th. Cowen restated a “buy” rating and set a $49.00 target price on shares of Juno Therapeutics in a research report on Friday, October 27th. Citigroup restated a “buy” rating and set a $59.00 target price on shares of Juno Therapeutics in a research report on Tuesday, October 31st. SunTrust Banks upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 2nd. Finally, Wedbush restated an “outperform” rating and set a $64.00 target price (up previously from $42.00) on shares of Juno Therapeutics in a research report on Thursday, November 2nd. Two research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $51.20.

In other Juno Therapeutics news, CEO Hans Edgar Bishop sold 270,250 shares of Juno Therapeutics stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $46.17, for a total value of $12,477,442.50. Following the transaction, the chief executive officer now owns 2,772,679 shares in the company, valued at approximately $128,014,589.43. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Robert Azelby sold 1,816 shares of Juno Therapeutics stock in a transaction on Monday, December 18th. The shares were sold at an average price of $44.96, for a total transaction of $81,647.36. Following the completion of the transaction, the executive vice president now owns 70,832 shares in the company, valued at approximately $3,184,606.72. The disclosure for this sale can be found here. In the last quarter, insiders sold 465,377 shares of company stock worth $26,375,636. 15.08% of the stock is owned by company insiders.

Several hedge funds have recently modified their holdings of the company. The Manufacturers Life Insurance Company raised its stake in shares of Juno Therapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 228 shares during the period. Aperio Group LLC raised its stake in shares of Juno Therapeutics by 4.2% in the 3rd quarter. Aperio Group LLC now owns 29,554 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 1,194 shares during the period. SG Americas Securities LLC raised its stake in shares of Juno Therapeutics by 9.5% in the 3rd quarter. SG Americas Securities LLC now owns 15,254 shares of the biopharmaceutical company’s stock valued at $684,000 after acquiring an additional 1,328 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Juno Therapeutics by 8.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,196 shares of the biopharmaceutical company’s stock valued at $786,000 after acquiring an additional 1,404 shares during the period. Finally, Advisor Group Inc. raised its stake in shares of Juno Therapeutics by 141.1% in the 3rd quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 1,439 shares during the period. 69.32% of the stock is currently owned by institutional investors and hedge funds.

Shares of Juno Therapeutics (NASDAQ:JUNO) opened at $85.60 on Friday. Juno Therapeutics has a 1 year low of $19.62 and a 1 year high of $86.28. The stock has a market cap of $9,780.00, a P/E ratio of -25.25 and a beta of 3.42. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.77 and a current ratio of 4.77.

TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Anticipate Juno Therapeutics Inc (JUNO) to Post -$1.15 EPS” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/04/zacks-analysts-anticipate-juno-therapeutics-inc-juno-to-post-1-15-eps.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Get a free copy of the Zacks research report on Juno Therapeutics (JUNO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply